EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026.

Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the page of Emergent’s website.

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our and follow us on , , , and .

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

  

Media Contact:

Assal Hellmer

Vice President, Communications



EN
16/04/2026

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

EBS Emergent BioSol...

Moody's Ratings affirms Emergent BioSolutions' B3 CFR; stable outlook

Rating Action: Moody's Ratings affirms Emergent BioSolutions' B3 CFR; stable outlook. Global Credit Research- 17 Apr 2026. New York, April 17, 2026-- Moody's Ratings affirmed the ratings of Emergent BioSolutions Inc. including the B3 Corporate Family Rating, the B3-PD Probability of Default Rating and the Caa1 senior unsecured rating.

EBS EMERGENT BIOSOLUTIONS INC.
17h / 12m 17h / 12m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Report First Quarter 2026 Financial Results o...

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026 GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing ho...

April 16, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-...

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation plan GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company has closed on a new credit facility agreement with for a new $150 million term loan. The proceeds from the new Term Loan were used to repay all amounts outstanding under the previous ...

April 16, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Partners with British Columbia to Supply NARCAN®...

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program). This order follows an additional investment of $18 million CAD by the B.C. government to expand the BC THN Program to include nasal naloxone. This is an expansion of B.C.’s...

April 9, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Participates in Upcoming International Preparedn...

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its products business, medical affairs, government and public affairs teams will participate in the following international preparedness conferences: , April 10-11, London, United Kingdom, May 19-21, Arcachon, France, June 9-12, Kuala Lumpur, Malaysia, June 20-22, San Diego, California, United Sta...

April 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch